Zafgen Inc (NASDAQ:ZFGN) Expected to Post Earnings of -$0.19 Per Share

Equities research analysts expect that Zafgen Inc (NASDAQ:ZFGN) will announce earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zafgen’s earnings. Zafgen posted earnings per share of ($0.39) during the same quarter last year, which suggests a positive year-over-year growth rate of 51.3%. The business is expected to announce its next quarterly earnings results on Monday, March 9th.

According to Zacks, analysts expect that Zafgen will report full-year earnings of ($1.21) per share for the current year. For the next year, analysts forecast that the company will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.13) to ($0.74). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Zafgen.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.03.

A number of brokerages have commented on ZFGN. Roth Capital cut shares of Zafgen from a “buy” rating to a “neutral” rating in a research report on Friday, September 6th. Wedbush reaffirmed a “hold” rating and issued a $0.78 price objective on shares of Zafgen in a research note on Thursday, November 14th. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Thursday, November 21st. Finally, JMP Securities cut shares of Zafgen from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 5th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Zafgen presently has an average rating of “Hold” and an average price target of $6.01.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC lifted its position in Zafgen by 2.2% in the second quarter. Citadel Advisors LLC now owns 971,818 shares of the biopharmaceutical company’s stock valued at $1,156,000 after purchasing an additional 20,953 shares during the last quarter. AWM Investment Company Inc. lifted its position in shares of Zafgen by 32.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock worth $2,210,000 after purchasing an additional 454,874 shares during the period. Morgan Stanley lifted its position in shares of Zafgen by 150.8% in the 2nd quarter. Morgan Stanley now owns 184,606 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 110,989 shares during the period. Wedbush Securities Inc. lifted its position in shares of Zafgen by 122.2% in the 3rd quarter. Wedbush Securities Inc. now owns 170,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 93,500 shares during the period. Finally, Northeast Financial Consultants Inc bought a new stake in shares of Zafgen during the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 61.52% of the company’s stock.

NASDAQ:ZFGN traded up $0.01 during mid-day trading on Wednesday, reaching $0.80. The stock had a trading volume of 3,247 shares, compared to its average volume of 338,672. The stock has a market capitalization of $30.27 million, a P/E ratio of -0.43 and a beta of -0.56. The firm has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.11 and a current ratio of 5.11. Zafgen has a one year low of $0.63 and a one year high of $5.76.

Zafgen Company Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Further Reading: Current Ratio

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit